Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
We’re Seeing Derangement of Climate System: Jeffrey Sachs
39:10 - March 3 -- The Earth Institute Director Jeffrey Sachs discusses climate change and sustainability on “Bottom Line.”
  • Netanyahu Is Wrong on Iran Issues: Jeffrey Sachs
  • GOP: House to Vote on Homeland Security Bill
  • First Look: $1M Armored Mercedes-Maybach Pullman